Market Overview - The Shanghai Composite Index closed at 3696.77 points, above the annual line, with an increase of 0.83% [1] - The total trading volume of A-shares reached 22,728.38 billion yuan [1] Stocks Breaking Annual Line - A total of 97 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Mingyang Electric: 8.12% deviation, closing price at 43.45 yuan, with a daily increase of 14.49% and turnover rate of 11.79% [1] - Baike Biological: 6.78% deviation, closing price at 25.40 yuan, with a daily increase of 8.09% and turnover rate of 2.70% [1] - ST Lianchuang: 5.16% deviation, closing price at 5.49 yuan, with a daily increase of 5.78% and turnover rate of 3.46% [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Times Electric: 3.99% deviation, closing price at 4.01 yuan, with a daily increase of 4.16% and turnover rate of 1.11% [1] - Xinda Real Estate: 3.99% deviation, closing price at 39.82 yuan, with a daily increase of 8.35% and turnover rate of 5.62% [1] - China National Materials: 3.76% deviation, closing price at 9.01 yuan, with a daily increase of 4.16% and turnover rate of 3.74% [1]

金融界消息 截至2025年8月14日收盘，百克生物（688276）报收于23.5元，下跌2.65%，换手率1.29%， 成交量5.32万手，成交金额1.27亿元。 天眼查商业履历信息显示，长春百克生物科技股份公司，成立于2004年，位于长春市，是一家以从事医 药制造业为主的企业。企业注册资本41365.7598万人民币，实缴资本36010万人民币。公司法定代表人 为李秀峰。 通过天眼查大数据分析，长春百克生物科技股份公司共对外投资了7家企业，参与招投标项目1039次， 知识产权方面有商标信息33条，专利信息69条，此外企业还拥有行政许可133个。 来源：金融界 资金流向方面，今日主力资金净流出2938.88万元，占比成交额23.18%。其中，超大单净流出2261.76万 元、占成交额17.84%，大单净流出677.12万元、占成交额5.34%，中单净流出流入2129.91万元、占成交 额16.8%，小单净流入808.96万元、占成交额6.38%。 百克生物最新一期业绩显示，截至2025一季报，公司营业总收入1.62亿元、同比减少39.96%，归属净利 润106.43万元，同比减少98.24%，扣非净利润341 ...

Group 1 - The Shanghai Composite Index closed at 3635.13 points, above the annual line, with a slight decline of 0.12% [1] - The total trading volume of A-shares reached 17363.03 billion yuan [1] - A total of 35 A-shares have surpassed the annual line today, with notable stocks including Tianshan Co., Sany Heavy Energy, and Wantong Development, showing divergence rates of 7.78%, 7.56%, and 7.37% respectively [1] Group 2 - The stocks with the highest divergence rates from the annual line include: - Tianshan Co. (10.06% increase, 1.70% turnover rate, annual line at 5.38 yuan, latest price at 5.80 yuan, divergence rate 7.78%) [1] - Sany Heavy Energy (11.05% increase, 5.83% turnover rate, annual line at 25.88 yuan, latest price at 27.84 yuan, divergence rate 7.56%) [1] - Wantong Development (9.94% increase, 7.44% turnover rate, annual line at 7.11 yuan, latest price at 7.63 yuan, divergence rate 7.37%) [1] - Other stocks with smaller divergence rates that have just crossed the annual line include: - Yonggui Electric (3.82% increase, 10.44% turnover rate, annual line at 16.62 yuan, latest price at 17.12 yuan, divergence rate 3.02%) [1] - Landun Optoelectronics (6.61% increase, 15.78% turnover rate, annual line at 26.28 yuan, latest price at 26.92 yuan, divergence rate 2.42%) [1]

| 601139 | 深圳燃 | 0.92 | 0.30 | 6.57 | 6.61 | 0.63 | | --- | --- | --- | --- | --- | --- | --- | | | 气 | | | | | | | 002813 | 路畅科 | 1.36 | 2.69 | 24.37 | 24.52 | 0.63 | | | 技 | | | | | | | 000966 | 长源电 | 0.66 | 0.71 | 4.58 | 4.60 | 0.45 | | | 力 | | | | | | | 601158 | 重庆水 | 0.43 | 0.12 | 4.70 | 4.72 | 0.35 | | | 务 | | | | | | | 000875 | 吉电股 | 1.35 | 0.84 | 5.24 | 5.25 | 0.25 | | | 份 | | | | | | | 002032 | 苏泊尔 | 0.21 | 0.08 | 51.32 | 51.39 | 0.14 | | 002157 | 正邦科 | 0.70 | 0.38 | 2.87 | 2.87 | 0.12 | | | 技 | | ...

证券代码：688276 证券简称：百克生物 公告编号：2025-026 经与会监事审议表决，一致通过如下议案： （一）审议通过《关于归还前次用于临时补充流动资金的募集资金暨使用 部分闲置募集资金临时补充流动资金的议案》 监事会认为：本次使用部分闲置募集资金临时补充流动资金系用于与主营业 务相关的生产经营，不会通过直接或者间接安排用于新股配售、申购，或者用于 股票及其衍生品种、可转换公司债券等的交易；不影响募集资金投资项目的正常 实施，亦不存在变相改变募集资金投向和损害中小股东利益的情形。综上，公司 监事会同意公司本次使用金额不超过人民币 10,000 万元的闲置募集资金临时补 充流动资金。 表决情况：同意 3 票，弃权 0 票，反对 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《长春百克生物科技股份公司关于归还前次用于临时补充流动资金的募集资金 暨使用部分闲置募集资金临时补充流动资金的公告》（公告编号：2025-025）。 长春百克生物科技股份公司 第六届监事会第三次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

归还前次用于临时补充流动资金的募集资金 暨使用部分闲置募集资金临时补充流动资金的核查意见 根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》《上海证券交易所科创 板股票上市规则》《科创板上市公司持续监管办法（试行）》等有关规定，作为长春 百克生物科技股份公司（以下简称"百克生物"或"公司"）首次公开发行股票并上市的 保荐机构，中信证券股份有限公司（以下简称"中信证券"）对百克生物归还前次用于 临时补充流动资金的募集资金暨使用部分闲置募集资金临时补充流动资金的情况进行 了核查，具体如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公开发行 股票注册的批复》（证监许可[2021]1594号）的同意，公司采用向社会公开发行方式 发行人民币普通股（A股）41,284,070股，发行价格为每股36.35元，募集资金总额 1,500,675,944.50元，扣除承销费、保荐费、审计费、律师费、信息披露等发行费用 104,881,526.35元后，实际募集资金净额为1,395,794,418.15元。上述 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-025 长春百克生物科技股份公司 关于归还前次用于临时补充流动资金的募集资金 暨使用部分闲置募集资金临时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025年7月25日，长春百克生物科技股份公司（以下简称"公司"或 "百克生物"）已将前次用于临时补充流动资金的募集资金10,000万元归还至 募集资金专用账户，并及时将募集资金归还情况通知保荐机构和保荐代表人。 公司拟使用不超过人民币10,000万元的闲置募集资金临时补充流动资金， 使用期限自公司董事会决议通过之日起不超过12个月。 上述资金到位情况经大信会计师事务所（特殊普通合伙）验证，并出具了大信 验字[2021]第7-00002号《长春百克生物科技股份公司验资报告》。 公司对募集资金采取了专户存储制度，前述募集资金到账后，已存放于募 集资金专户，并与保荐机构、募集资金专户监管银行签署《募集资金专户存储 三方监管协议》（以下简称"监管协议"）。监管协议与证券交易所监管协 ...

Group 1 - The core viewpoint of the news highlights a significant rise in virus prevention stocks, particularly in response to the reported cases of Chikungunya fever in Foshan, Guangdong Province [1][2][3] - Notable stock performances include Zhifei Biological, which increased by 16.86%, and Watson Bio, which rose by 13.39%, among others [2] - The total market capitalization of Zhifei Biological is reported at 57.7 billion, while Watson Bio stands at 21 billion [2] Group 2 - As of July 22, Foshan has reported a total of 3,195 confirmed cases of Chikungunya fever, primarily concentrated in the Shunde District [2] - The World Health Organization has issued a warning regarding mosquito-borne diseases, urging countries to prepare for potential outbreaks [3]

Group 1 - The A-share biopharmaceutical sector experienced a significant afternoon rally, with notable increases in stock prices [1] - Zhifei Biological surged over 14%, while Watson Bio rose more than 12% [1] - Other companies such as Kangtai Biological, Sanyuan Gene, Bohui Innovation, Baike Biological, and Zhixiang Jintai also saw gains [1]

Core Viewpoint - The article discusses the significant developments in the field of shingles vaccines in China, highlighting the price reduction initiatives and the emergence of domestic vaccine production, particularly by Changchun Baike Biotechnology Co., Ltd. [5][6] Group 1: Vaccine Market Dynamics - The shingles vaccine market in China is experiencing a price reduction trend, driven by the "Healthy China" strategy, which aims to enhance public health through affordable vaccination programs [5]. - There are currently two approved shingles vaccines in China: one imported and one domestically produced by a company based in Changchun, Jilin [5][6]. Group 2: Company Innovations and Developments - Changchun Baike Biotechnology has launched the first domestically developed live attenuated shingles vaccine for individuals aged 40 and above, breaking the monopoly of imported vaccines in the market [6]. - The parent company, Changchun High-tech Industry (Group) Co., Ltd., has shifted its focus towards innovation in the biopharmaceutical sector, investing over 8.5 billion yuan in research and development [6][8]. Group 3: Regional Industry Growth - The biopharmaceutical industry in Changchun is supported by a robust infrastructure and educational resources, including institutions like the Chinese Academy of Sciences and several key universities [8]. - The biopharmaceutical and life health industry in Changchun is projected to achieve a production value of 110 billion yuan in 2024, reflecting a year-on-year growth of 12.5% [8][11]. Group 4: Future Prospects - The "Yongchun Biopharmaceutical City" is under construction, with 33 projects and a total investment of 15.2 billion yuan, expected to generate a production value of 60 billion yuan by 2035 [11]. - The local government has introduced a three-year action plan to further develop the biopharmaceutical and life health industry as a new growth engine for the city's economy [11][13].